Table 3.
Prognostic Factors for Overall-Survival
| Factors | Univariate Analysis | Multivariate Analysis (Non-Adjusted) | Multivariate Analysis (Adjusted***) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | p* | HR | 95% CI | p** | HR | 95% CI | p** | |
| Age (years) | |||||||||
| <68 | |||||||||
| ≥68 | 1.02 | 0.64–1.63 | 0.932 | ||||||
| Gender | |||||||||
| Male | |||||||||
| Female | 1.11 | 1.42–3.13 | <0.001 | 1.02 | 0.63–1.65 | 0.933 | 1.08 | 0.63–1.83 | 0.788 |
| BMI (kg/m2) | |||||||||
| <25 | |||||||||
| ≥25 | 0.66 | 0.40–1.09 | 0.102 | ||||||
| ECOG PS | |||||||||
| 0–1 | |||||||||
| ≥2 | 2.16 | 1.41–3.30 | <0.001 | 1.88 | 1.22–2.90 | 0.004 | 1.81 | 1.15–2.85 | 0.010 |
| Tumor location | |||||||||
| Upper | |||||||||
| Middle | 0.65 | 0.37–1.16 | 0.144 | ||||||
| Lower | 0.83 | 0.47–1.46 | 0.508 | ||||||
| Overlapping | 1.07 | 0.51–2.25 | 0.860 | ||||||
| Pathology grade | |||||||||
| Well | |||||||||
| Moderately | 0.75 | 0.27–2.08 | 0.578 | ||||||
| Poorly | 0.85 | 0.30–2.36 | 0.750 | ||||||
| T classification | |||||||||
| T2 | |||||||||
| T3 | 0.69 | 0.42–1.13 | 0.144 | ||||||
| T4 | 0.76 | 0.46–1.25 | 0.278 | ||||||
| LN metastasis | |||||||||
| Absent | |||||||||
| Present | 2.07 | 1.17–3.67 | 0.013 | 1.98 | 1.08–3.63 | 0.028 | 1.87 | 0.97–3.61 | 0.063 |
| Distant metastasis | |||||||||
| Absent | |||||||||
| Present | 1.56 | 1.07–2.27 | 0.021 | 1.43 | 0.97–2.11 | 0.069 | 1.48 | 0.88–2.48 | 0.137 |
| sPD-L1 | |||||||||
| Low | |||||||||
| High | 3.96 | 2.51–6.26 | <0.001 | 3.71 | 2.05–6.71 | < 0.001 | 4.06 | 2.12–7.79 | < 0.001 |
| PD-L1 | |||||||||
| Low | |||||||||
| High | 0.98 | 0.67–1.42 | 0.898 | ||||||
| NLR | |||||||||
| <6.60 | |||||||||
| ≥6.60 | 1.57 | 1.03–2.31 | 0.036 | 1.72 | 1.08–2.74 | 0.021 | 1.69 | 1.05–2.70 | 0.030 |
| PLR | |||||||||
| <145 | |||||||||
| ≥145 | 1.29 | 0.75–2.23 | 0.360 | ||||||
| CRP (mg/L) | |||||||||
| <5.21 | |||||||||
| ≥5.21 | 1.55 | 1.02–2.36 | 0.038 | 1.29 | 0.84–2.00 | 0.2502 | 1.14 | 0.72–1.83 | 0.573 |
| ALB (g/L) | |||||||||
| <40.0 | |||||||||
| ≥40.0 | 1.39 | 0.95–2.02 | 0.093 | 1.27 | 0.85–1.90 | 0.251 | 1.24 | 0.80–1.92 | 0.337 |
| GLB (g/L) | |||||||||
| <25.7 | |||||||||
| ≥25.7 | 0.67 | 0.45–0.99 | 0.042 | 0.95 | 0.63–1.42 | 0.796 | 0.92 | 0.60–1.40 | 0.688 |
| LDH (U/L) | |||||||||
| <212 | |||||||||
| ≥212 | 0.76 | 0.51–1.14 | 0.182 | ||||||
Notes: *p<0.1 was considered significant in Univariate analysis. **p<0.05 was considered significant in Multivariate analysis.
Abbreviations: HR, hazard ratio; 95% CI, 95% confidence intervals; BMI, body mass index; ECOG PS, Eastern Cooperative Oncology Group performance score; LN metastasis, lymph node metastasis; NLR, neutrophil–lymphocyte ratio; PLR, platelet–lymphocyte ratio; CRP, C-reactive protein; ALB, albumin; GLB, globulin; LDH, lactate dehydrogenase.